サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1420963

巣状分節性糸球体硬化症市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年

Focal Segmental Glomerulosclerosis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 163 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
巣状分節性糸球体硬化症市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年
出版日: 2023年12月29日
発行: Transparency Market Research
ページ情報: 英文 163 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

巣状分節性糸球体硬化症市場 - レポートの範囲

世界の巣状分節性糸球体硬化症市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。レポートは、世界の巣状分節性糸球体硬化症の収益を提供します。 2023年を基準年、2031年を予測年とみなして、2017年から2031年の期間の市場を分析します。レポートは、2023年から2031年までの世界の巣状分節性糸球体硬化症市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、巣状分節性糸球体硬化症市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 5億3,850万米ドル
2031年の市場価値 9億5,620万米ドル
CAGR 6.5%

このレポートは、世界の巣状分節性糸球体硬化症市場の競合情勢を詳しく掘り下げています。世界の巣状分節性糸球体硬化症市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の巣状分節性糸球体硬化症市場の企業の属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017年～2031年

第5章 重要な洞察

  • パイプライン分析
  • 主要な疾患の種類/ブランド分析
  • 主な合併と買収
  • COVID-19感染症のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：疾患タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：疾患別、2017年～2031年
    • 一次
    • 二次
  • 市場魅力度分析：疾患タイプ別

第7章 世界市場の分析と予測：疾病管理別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：疾病管理別、2017年～2031年
    • 診断
      • 腎生検
      • クレアチニン検査
      • その他
    • 処理
      • 薬物セラピー
      • 透析
      • 腎臓移植
  • 市場魅力分析：疾病管理別

第8章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017年～2031年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第9章 北米市場の分析と予測

第10章 欧州市場の分析と予測

第11章 アジア太平洋市場の分析と予測

第12章 ラテンアメリカ市場の分析と予測

第13章 中東・アフリカ市場の分析と予測

第14章 競合情勢

  • 市場企業 - 競争マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Variant Pharmaceuticals, Inc.
    • ChemoCentryx, Inc.
    • Travere Therapeutics
    • AbbVie, Inc.
    • Novartis AG
    • Pfizer, Inc.
    • AstraZeneca plc.
    • Sanofi SA
    • GlaxoSmithKline plc.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Tables

  • Table 01: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 02: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031
  • Table 03: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 05: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 06: North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031
  • Table 07: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 8: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 9: Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031
  • Table 10: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 11: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 12: Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031
  • Table 13: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 15: Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031
  • Table 16: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2017-2031
  • Table 18: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2017-2031

List of Figures

  • Figure 01: Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
  • Figure 02: Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn), by Disease Type, 2022
  • Figure 03: Global Focal Segmental Glomerulosclerosis Market Value Share, by Disease Type, 2022
  • Figure 04: Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn), by Disease Management, 2022
  • Figure 05: Global Focal Segmental Glomerulosclerosis Market Value Share, by Disease Management, 2022
  • Figure 06: Global Focal Segmental Glomerulosclerosis Market Value Share, by Region, 2022
  • Figure 07: Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 08: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 09: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 10: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2023 and 2031
  • Figure 11: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
  • Figure 12: Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 13: Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 14: North America Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 15: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 16: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 17: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 18: North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
  • Figure 19: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 20: North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
  • Figure 21: Europe Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 22: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 23: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 24: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 25: Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
  • Figure 26: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 27: Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
  • Figure 28: Asia Pacific Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 29: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 30: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 31: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 32: Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
  • Figure 33: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 34: Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
  • Figure 35: Latin America Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 36: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 37: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 38: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 39: Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
  • Figure 40: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 41: Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
  • Figure 42: Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 43: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 44: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 45: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2022 and 2031
  • Figure 46: Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2022 and 2031
  • Figure 47: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2023-2031
  • Figure 48: Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2023-2031
目次
Product Code: TMRGL31505

Focal Segmental Glomerulosclerosis Market - Scope of Report

TMR's report on the global focal segmental glomerulosclerosis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global focal segmental glomerulosclerosis market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global focal segmental glomerulosclerosis market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the focal segmental glomerulosclerosis market.

Market Snapshot
Market Value in 2023US$ 538.5 Mn
Market Value in 2031US$ 956.2 Mn
CAGR6.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global focal segmental glomerulosclerosis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global focal segmental glomerulosclerosis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global focal segmental glomerulosclerosis market.

The report delves into the competitive landscape of the global focal segmental glomerulosclerosis market. Key players operating in the global focal segmental glomerulosclerosis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global focal segmental glomerulosclerosis market profiled in this report.

Key Questions Answered in Global focal segmental glomerulosclerosis Market Report:

  • What is the sales/revenue generated by focal segmental glomerulosclerosis across all regions during the forecast period?
  • What are the opportunities in the global focal segmental glomerulosclerosis market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Focal Segmental Glomerulosclerosis Market - Research Objectives and Research Approach

The comprehensive report on the global focal segmental glomerulosclerosis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global focal segmental glomerulosclerosis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global focal segmental glomerulosclerosis market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Focal Segmental Glomerulosclerosis Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Disease Type Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Disease Type/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Disease Type, 2017-2031
    • 6.3.1. Primary Focal Segmental Glomerulosclerosis
    • 6.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 6.4. Market Attractiveness Analysis, by Disease Type

7. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Management

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Management, 2017-2031
    • 7.3.1. Diagnosis
      • 7.3.1.1. Kidney Biopsy
      • 7.3.1.2. Creatinine Test
      • 7.3.1.3. Others
    • 7.3.2. Treatment
      • 7.3.2.1. Drug Therapy
      • 7.3.2.2. Dialysis
      • 7.3.2.3. Kidney Transplant
  • 7.4. Market Attractiveness Analysis, by Disease Management

8. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Focal Segmental Glomerulosclerosis Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Disease Type, 2017-2031
    • 9.3.1. Primary Focal Segmental Glomerulosclerosis
    • 9.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 9.4. Market Value Forecast, by Disease Management, 2017-2031
    • 9.4.1. Diagnosis
      • 9.4.1.1. Kidney Biopsy
      • 9.4.1.2. Creatinine Test
      • 9.4.1.3. Others
    • 9.4.2. Treatment
      • 9.4.2.1. Drug Therapy
      • 9.4.2.2. Dialysis
      • 9.4.2.3. Kidney Transplant
  • 9.5. Market Value Forecast, by Country, 2017-2031
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Disease Type
    • 9.6.2. By Disease Management
    • 9.6.3. By Country

10. Europe Focal Segmental Glomerulosclerosis Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Disease Type, 2017-2031
    • 10.3.1. Primary Focal Segmental Glomerulosclerosis
    • 10.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 10.4. Market Value Forecast, by Disease Management, 2017-2031
    • 10.4.1. Diagnosis
      • 10.4.1.1. Kidney Biopsy
      • 10.4.1.2. Creatinine Test
      • 10.4.1.3. Others
    • 10.4.2. Treatment
      • 10.4.2.1. Drug Therapy
      • 10.4.2.2. Dialysis
      • 10.4.2.3. Kidney Transplant
  • 10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Disease Type
    • 10.6.2. By Disease Management
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Disease Type, 2017-2031
    • 11.3.1. Primary Focal Segmental Glomerulosclerosis
    • 11.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 11.4. Market Value Forecast, by Disease Management, 2017-2031
    • 11.4.1. Diagnosis
      • 11.4.1.1. Kidney Biopsy
      • 11.4.1.2. Creatinine Test
      • 11.4.1.3. Others
    • 11.4.2. Treatment
      • 11.4.2.1. Drug Therapy
      • 11.4.2.2. Dialysis
      • 11.4.2.3. Kidney Transplant
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Disease Type
    • 11.6.2. By Disease Management
    • 11.6.3. By Country/Sub-region

12. Latin America Focal Segmental Glomerulosclerosis Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Disease Type, 2017-2031
    • 12.3.1. Primary Focal Segmental Glomerulosclerosis
    • 12.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 12.4. Market Value Forecast, by Disease Management, 2017-2031
    • 12.4.1. Diagnosis
      • 12.4.1.1. Kidney Biopsy
      • 12.4.1.2. Creatinine Test
      • 12.4.1.3. Others
    • 12.4.2. Treatment
      • 12.4.2.1. Drug Therapy
      • 12.4.2.2. Dialysis
      • 12.4.2.3. Kidney Transplant
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Disease Type
    • 12.6.2. By Disease Management
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Disease Type, 2017-2031
    • 13.3.1. Primary Focal Segmental Glomerulosclerosis
    • 13.3.2. Secondary Focal Segmental Glomerulosclerosis
  • 13.4. Market Value Forecast, by Disease Management, 2017-2031
    • 13.4.1. Diagnosis
      • 13.4.1.1. Kidney Biopsy
      • 13.4.1.2. Creatinine Test
      • 13.4.1.3. Others
    • 13.4.2. Treatment
      • 13.4.2.1. Drug Therapy
      • 13.4.2.2. Dialysis
      • 13.4.2.3. Kidney Transplant
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Disease Type
    • 13.6.2. By Disease Management
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Variant Pharmaceuticals, Inc.
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Disease Type Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. ChemoCentryx, Inc.
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Disease Type Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Travere Therapeutics
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Disease Type Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. AbbVie, Inc.
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Disease Type Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Novartis AG
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Disease Type Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Pfizer, Inc.
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Disease Type Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. AstraZeneca plc.
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Disease Type Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Sanofi S.A.
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Disease Type Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. GlaxoSmithKline plc.
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Disease Type Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Disease Type Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview